• Profile
Close

Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials

Diabetes, Obesity and Metabolism Dec 24, 2021

Jódar E, Romera I, Wang Q, et al. - By conducting post hoc analyses, data were pooled from randomized, phase 3 studies (n=6) assessing the relationship between treatment with dulaglutide 1.5 mg once weekly and glycaemic variability (GV) in adult patients with type 2 diabetes mellitus (T2D).

  • Dulaglutide for T2D administered as monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment, was found to be potentially linked with a decrease in GV.

  • A reduction in GV to a greater degree was achieved with dulaglutide vs insulin glargine.

  • When added to insulin glargine, dulaglutide treatment was shown to be related to greater reductions in GV than insulin glargine alone.

  • Observations from this study may be clinically relevant as decreased GV may be linked with better outcomes.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay